Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
Go back to Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity| Merck & Co. (NYSE: MRK) | Delayed: 132.37 +1.95 (1.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.42 | 52 Week High | $65.46 | |||
| Open | $130.25 | 52 Week Low | $47.97 | |||
| Day High | $132.60 | P/E | 90.05 | |||
| Day Low | $128.91 | EPS | $1.47 | |||
| Volume | 2,779,480 | |||||
